KaliVir Immunotherapeutics, Inc., a clinical‑stage biotechnology company developing cutting‑edge, multi‑mechanistic oncolytic immunotherapy programs, has announced the closing of a US$14 million extension of its Series A financing. The financing was led by Company K Partners, with participation from SV Investment, Flexus Partners, as well as continued support from existing investors including affiliates of Nextrans and Quad Investment Management.
Latham & Watkins LLP represents KaliVir Immunotherapeutics in the financing with an Emerging Companies & Growth team led by New York partner Eli Curi, with associates Saem Kim and Adithi Iyer.
Where the legal industry reads first.
Enjoyed this article? Get the biggest legal industry updates, deals, appointments, insights and expert interviews in your inbox, free.
No spam. Unsubscribe anytime.